IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
Phase 3 French biotech developing therapies for NASH.
Industry: Health Care
Latest Trade: $5.10 +0.10 (+2.0%)
First Day Return: +9.1%
Return from IPO: -75.4%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 02/27/2019 |
Offer Price | $20.32 |
Price Range $20.32 - $20.32 | |
Offer Shares (mm) | 6.7 |
Deal Size ($mm) | $135 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 03/26/2019 |
Offer Price | $20.32 |
Price Range $20.32 - $20.32 | |
Offer Shares (mm) | 6.7 |
Deal Size ($mm) | $135 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
more |
Company Data | |
---|---|
Headquarters | Loos, France |
Founded | 1999 |
Employees | 150 |
Website www.genfit.com |